Form 4: UTHR CFO Edgemond Exercises Options, Sells Shares
Insider Transaction Report
United Therapeutics CFO James Edgemond exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.
Summary
- CFO James Edgemond exercised 3,517 stock options at an exercise price of $146.03 per share on December 15, 2025.
- Concurrently, Edgemond sold 3,517 shares of common stock in multiple transactions on December 15, 2025, at weighted average prices ranging from $491.525 to $500.303.
- These transactions were executed under a Rule 10b5-1 trading plan established on August 5, 2025.
- The filing also corrects a previous underreporting error, noting that 24 shares acquired on September 4, 2025, via the United Therapeutics Corporation Stock Purchase Plan were not included in prior Form 4s filed in November 2025.
- Following these reported transactions, Edgemond beneficially owns 8,142 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral. The transactions are routine for an executive managing their equity compensation through a pre-planned 10b5-1 program. The correction of a minor reporting error is also a standard compliance update.
Positives
- The exercise of stock options indicates the reporting person saw value in converting options to shares.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a systematic approach to managing equity rather than a reaction to immediate company news.
Negatives
- The sale of shares by a key executive, even if pre-planned, reduces their direct equity stake in the company.
- A previous reporting error led to an underreporting of 24 shares in earlier Form 4 filings.
Risks
- NA
Future Outlook
NA
Industry Context
This Form 4 filing details an executive's personal stock transactions and does not provide information directly related to broader industry trends or competitive landscape for United Therapeutics Corp.
Comparison to Industry Standards
- NA
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders may note the executive's decision to exercise options and sell shares, which is a common practice for managing equity compensation, especially given the pre-planned nature under Rule 10b5-1.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2020-03-15 | Date stock options became exercisable. |
| 2025-08-05 | Date Rule 10b5-1 trading plan was entered into. |
| 2025-09-04 | Date 24 shares were acquired under the United Therapeutics Corporation Stock Purchase Plan, previously underreported. |
| 2025-11-05 | Date of a previously filed Form 4 that underreported shares. |
| 2025-11-12 | Date of a previously filed Form 4 that underreported shares. |
| 2025-11-18 | Date of a previously filed Form 4 that underreported shares. |
| 2025-12-15 | Date of stock option exercise and subsequent share sales. |
| 2025-12-16 | Date the Form 4 was signed. |
| 2027-03-15 | Expiration date of the exercised stock options. |
Recommendation
holdThis Form 4 filing details routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or performance. The minor correction of a previous reporting error is also a standard compliance matter. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is maintained, pending further substantive company news.
Keywords
United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, James Edgemond, CFO, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.